Sarah Ibrahim is the Associate Director for (Generic Drug) Stakeholder and Global Engagement in the Office of Generic Drugs (OGD)/ Center of Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA). In this role, Dr. Ibrahim develops OGD strategies to address identified and emerging regulatory challenges in relation to the international nature of the generic drug industry. In collaboration with other CDER and FDA offices, she supports stakeholder engagement concerning issues related to globalization of the generic pharmaceutical supply and harmonization of regulatory approaches for generic drugs.
Dr. Ibrahim received her PhD in Biopharmaceutics/Pharmaceutics from the School of Pharmacy, University of Cincinnati and a B.S. in Pharmacy and Pharmaceutical Sciences from Cairo University, Egypt. Dr. Ibrahim started her career at the FDA in 2014 as a scientific reviewer in the Office of Pharmaceutical Quality. Prior to her FDA career, she has years of experience in the US pharmaceutical industry in the area of pharmaceutical development. As an assistant professor, along with the founding faculty, Dr. Ibrahim established the pharmaceutical sciences department for the second school of pharmacy in the state of New Jersey.